Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors
April 19, 2022 08:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
April 13, 2022 09:00 ET
|
Ceapro Inc.
– FY 2021 record sales of $17,200,000 compared to $15,100,000 for FY 2020, representing a 14% increase year over year; Ceapro’s best sales performance in Company history – Net profit of $2,842,000...
Ceapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
March 10, 2022 09:05 ET
|
Ceapro Inc.
- Symrise to distribute and commercialize Ceapro’s high value active ingredients in the cosmetic market - - Supply and distribution agreement provides Symrise with exclusivity for several major key...
Ceapro Bolsters Board of Directors with Appointment of Top Executive from Global Pharmaceutical Industry
March 02, 2022 08:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, March 02, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. to Present at the Virtual Investor 2022 Top Picks Conference
January 20, 2022 09:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Announces R&D Funding to Support PGX Technology Project
November 29, 2021 08:05 ET
|
Ceapro Inc.
– PGX Technology further recognized as a disruptive technology – Additional support paves the way for the manufacturing of pharmaceutical-grade yeast beta glucan (YBG) EDMONTON, Alberta, Nov. 29,...
Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational Highlights
November 17, 2021 09:00 ET
|
Ceapro Inc.
– Increased R&D activities focused on the completion of a clinical trial for oat beta glucan as a potential cholesterol reducer and on the development of yeast beta glucan as a potential inhalable...
Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol Levels
November 17, 2021 07:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic Using Yeast Beta Glucan Processed with Pressurized Gas eXpanded Technology (PGX-YBG)
November 11, 2021 08:35 ET
|
Ceapro Inc.
McMaster’s research team discovers new mechanism of action for PGX-YBG PGX-YBG demonstrates ability to reprogram macrophages on its own PGX-YBG may be a suitable therapeutic solution for patients...
Ceapro Inc. to Present at the Virtual Investor Roundtable Event
November 10, 2021 09:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...